Supplementary Online Content
|
|
|
- James Skinner
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M. Use of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and metaanalysis of the risk of cardiovascular events, major molecular response, and overall survival. JAMA Oncology. Publish online February 4, 016. doi: /jamaoncol emethods 1: Search strategy emethods : List of vascular occlusive adverse events efigure 1: Flow diagram of study selection according to PRISMA (preferr reporting items for systematic reviews and meta-analysis) statement etable 1: Characteristics of includ clinical trials and quality assessment efigure : Evaluation of publications bias etable : Rates of outcomes of interest across the includ studies stratifi by treatment efigure 3: One-way sensitivity analysis of the risk of vascular occlusive events in the leukemic population and stratifi by treatment efigure 4: One-way sensitivity analysis for the overall survival at 1 year and for the major molecular response rate. This supplementary material has been provid by the authors to give readers additional information about their work. 015 American Mical Association. All rights reserv.
2 emethods 1: Search strategy A. bosutinib Database: PubM: 1946 to September 1th 014 (5) update October 1th bosutinib [Title] (60) Bosutinib [Title]. SKI-606 [Title] (17) SKI-606 [Title] 3. SKI606 [Title] (1) 4. ((#1) OR #) OR #3) (70) ((bosutinib[title]) OR SKI-606[Title]) OR SKI606[Title] 5. (#4) [and] "randomiz controll trial" (5) (#4) AND "randomiz controll trial"[all Fields] 6. (#4) [and] "randomiz trial" (0) (#4) AND "randomiz trial"[all Fields] 7. (#4) AND "randomiz clinical trial" (0) (#4) AND "randomiz clinical trial"[all Fields] 8. (#4) [and] "randomis controll trial" (0) (#4) AND "randomiz controll trial"[all Fields] 9. (#4) [and] "randomis trial" (0) (#4) AND "randomiz trial"[all Fields] 10. (#4) AND "randomis clinical trial" (0) (#4) AND "randomiz clinical trial"[all Fields] 11. (((((#5) OR #6) OR #7) OR #8) OR #9) OR #10 (5) (((((#5) OR #6) OR #7) OR #8) OR #9) OR #10 Database: Scopus: 1946 to September 1th 014 (14) update October 1th TITLE (bosutinib) (73). TITLE (SKI-606) (18) 3. TITLE (SKI606) (1) 4. ( TITLE ( bosutinib ) ) OR ( TITLE ( ski-606 ) ) OR ( TITLE ( ski606 ) ) (83) 5. ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomiz controll trial" ) ) (11) 6. ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomiz trial" ) ) (3) 7. ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomiz clinical trial" ) ) (1) 8. ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomis controll trial" ) ) (11) 9. ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomis trial" ) ) (3) 10. ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomis clinical trial" ) ) (1) 11. #10 OR #9 OR #8 OR #7 OR #6 OR #5 ( ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomis clinical trial" ) ) ) OR ( ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomis trial" ) ) ) OR ( ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomis controll trial" ) ) ) OR ( ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomiz clinical trial" ) ) ) OR ( ( TITLE ( ski606 ) OR TITLE (
3 ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomiz trial" ) ) ) OR ( ( TITLE ( ski606 ) OR TITLE ( ski-606 ) OR TITLE ( bosutinib ) AND ALL ( "randomiz controll trial" ) ) ) (14) Database: The Cochrane Library (all Cochrane product) : From 197 to September 1th 014 (8) update October 1th bosutinib (17). SKI-606 (8) 3. SKI606 (0) 4. #1 or # or #3 (17) 5. #4 and «randomiz controll trial» (8) 6. #4 and «randomiz trials» (0) 7. #4 and «randomiz clinical trial» (0) 8. #4 and «randomis controll trials» (8) 9. #4 and «randomis trial» (0) 10. #4 and «randomis clinical trials» (0) 11. #5 or #6 or #7 or #8 or #9 or #10 (8) Then only «Trials» results were includ in the meta-analysis (8) B. dasatinib Database: PubM : 1946 to September, 15th 014 (3) update October 1th Dasatinib [title] (680) Dasatinib[title]. BMS [title] (6) BMS-35485[title] 3. BMS35485 [title] (1) Search details : BMS35485[title] 4. ((#1) OR #) OR #3 (686) ((#1) OR #) OR #3) 5. (#4) [and] "randomiz controll trial" (19) (#4) AND "randomiz controll trial"[all Fields] 6. (#4) [and] "randomiz trial" (4) (#4) AND "randomiz trial"[all Fields] 7. (#4) AND "randomiz clinical trial" (0) (#4) AND "randomiz clinical trial"[all Fields] 8. (#4) [and] "randomis controll trial" (1) (#4) AND "randomiz controll trial"[all Fields] 9. (#4) [and] "randomis trial" (0) (#4) AND "randomiz trial"[all Fields] 10. (#4) AND "randomis clinical trial" (1) (#4) AND "randomiz clinical trial"[all Fields] 11. (((((#5) OR #6) OR #7) OR #8) OR #9) OR #10 (3) (((((#5) OR #6) OR #7) OR #8) OR #9) OR #10 Database: Scopus : 1946 to September 15th 014 (71) update October 1th TITLE(dasatinib) (76) 3
4 . TITLE(BMS-35485) (8) 3. TITLE(BMS35485) () 4. (TITLE(dasatinib)) OR (TITLE(BMS-35485) OR (TITLE(BMS35485)) (770) 5. ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomiz clinical trial" ) ) (4) 6. ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomiz trial" ) ) (3) 7. ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomiz controll trial" ) ) (49) 8. ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomis clinical trial" ) ) (4) 9. ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomis trial" ) ) (3) 10. ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomis controll trial" ) ) (49) 11. ( ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomiz clinical trial" ) ) ) OR ( ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomiz controll trial" ) ) ) OR ( ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomiz trial" ) ) ) OR ( ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomis trial" ) ) ) OR ( ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomis controll trial" ) ) ) OR ( ( TITLE ( bms35485 ) OR TITLE ( bms ) OR TITLE ( dasatinib ) AND ALL ( "randomis clinical trial" ) ) ) (71) Database : The Cochrane Library (all Cochrane product) : From 197 to 014 (34) update October 1th dasatinib (108). BMS (1) 3. BMS35485 (0) 4. #1 or # or #3 (108) 5. #4 and «randomiz controll trial» (33) 6. #4 and «randomis controll trials» (1) 7. #4 and «randomiz clinical trial» (1) 8. #4 and «randomis clinical trials» (0) 9. #4 and «randomiz trial» (3) 10. #4 and «randomis trials» (0) 11. #5 or #6 or #7 or #8 or #9 or #10 (35) Then only «Trials» results were includ in the meta-analysis (34) C. nilotinib Database: PubM : 1946 to September 1th 014 (17) update October 1th nilotinib [Title] (408) Nilotinib [Title]. AMN107 [Title] (33) AMN107 [Title] 3. ((#1) OR #) (45) (Nilotinib[Title]) OR AMN107[Title] 4. (#3) [and] "randomiz controll trial" (15) (#3) AND "randomiz controll trial"[all Fields] 5. (#3) [and] "randomiz trial" (1) (#3) AND "randomiz trial"[all Fields] 6. (#3) AND "randomiz clinical trial" (0) 4
5 (#3) AND "randomiz clinical trial"[all Fields] 7. (#3) [and] "randomis controll trial" (1) (#3) AND "randomiz controll trial"[all Fields] 8. (#3) [and] "randomis trial" (0) (#3) AND "randomiz trial"[all Fields] 9. (#3) AND "randomis clinical trial" (1) (#3) AND "randomiz clinical trial"[all Fields] 10. (((((#4) OR #5) OR #6) OR #7) OR #8) OR #9 (17) (((((#4) OR #5) OR #6) OR #7) OR #8) OR #9 Database: Scopus : 1946 to September 1th 014 (60) update October 1th TITLE (nilotinib) (47). TITLE(AMN107) (37) 3. ( TITLE ( nilotinib ) ) OR ( TITLE ( amn107 ) ) (49) 4. ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomiz controll trial" ) ) (50) 5. ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomiz trial" ) ) () 6. ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomiz clinical trial" ) ) (1) 7. ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomis controll trial" ) ) (50) 8. ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomis trial" ) ) () 9. ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomis clinical trial" ) ) (1) 10. #9 OR #8 OR #7 OR #6 OR #5 OR #4 ( ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomis clinical trial" ) ) ) OR ( ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomis trial" ) ) ) OR ( ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomis controll trial" ) ) ) OR ( ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomiz clinical trial" ) ) ) OR ( ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomiz trial" ) ) ) OR ( ( TITLE ( amn107 ) OR TITLE ( nilotinib ) AND ALL ( "randomiz controll trial" ) ) ) (60) Database: The Cochrane Library (all Cochrane product) : From 197 to September 1th 014 (50) update October 1th nilotinib (68). AMN107 () 3. #1 or # (70) 4. #3 and «randomiz controll trial» (68) 5. #3 and «randomiz trials» (68) 6. #3 and «randomiz clinical trial» (68) 7. #3 and «randomis controll trials» (68) 8. #3 and «randomis trial» (68) 9. #3 and «randomis clinical trials» (68) 10. #4 or #5 or #6 or #7 or #8 or #9 (68) Then only «Trials» results were includ in the meta-analysis (50) D. ponatinib Database: PubM : 1946 to September 1th 014 (1) update October 1th ponatinib [Title] (69) Ponatinib [Title]. AP4534 [Title] (8) AP4534[Title] 5
6 3. ((#1) OR #) (71) Ponatinib[Title] OR AP4534[Title] 4. (#3) [and] "randomiz controll trial" (1) (#3) AND "randomiz controll trial"[all Fields] 5. (#3) [and] "randomiz trial" (0) (#3) AND "randomiz trial"[all Fields] 6. (#3) AND "randomiz clinical trial" (0) (#3) AND "randomiz clinical trial"[all Fields] 7. (#3) [and] "randomis controll trial" (0) (#3) AND "randomiz controll trial"[all Fields] 8. (#3) [and] "randomis trial" (0) (#3) AND "randomiz trial"[all Fields] 9. (#3) AND "randomis clinical trial" (0) (#3) AND "randomiz clinical trial"[all Fields] 10. (((((#4) OR #5) OR #6) OR #7) OR #8) OR #9 (1) (((((#4) OR #5) OR #6) OR #7) OR #8) OR #9 Database: Scopus : 1946 to September 1th 014 (3) update October 1th TITLE (ponatinib) (87). TITLE(AP4534) (9) 3. ( TITLE ( AP4534 ) OR TITLE ( ponatinib ) ) (90) 4. ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomiz clinical trial" ) ) (0) 5. ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomiz trial" ) ) (1) 6. ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomiz clinical trial" ) ) (0) 7. ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomis controll trial" ) ) () 8. ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomis trial" ) ) (1) 9. ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomis clinical trial" ) ) (0) 10. #9 OR #8 OR #7 OR #6 OR #5 OR #4 ( ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomis clinical trial" ) ) ) OR ( ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomis trial" ) ) ) OR ( ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomis controll trial" ) ) ) OR ( ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomiz clinical trial" ) ) ) OR ( ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomiz trial" ) ) ) OR ( ( TITLE ( ap4534 ) OR TITLE ( ponatinib ) AND ALL ( "randomiz clinical trial" ) ) ) (3) Database: The Cochrane Library (all Cochrane product) : From 197 to September 1th 014 (3) update October 1th ponatinib (6). AP4534 (1) 3. #1 or # (6) 4. #3 and «randomiz controll trial» (6) 5. #3 and «randomiz trials» (6) 6. #3 and «randomiz clinical trial» (6) 7. #3 and «randomis controll trials» (6) 8. #3 and «randomis trial» (6) 9. #3 and «randomis clinical trials» (6) 10. #4 or #5 or #6 or #7 or #8 or #9 (6) Then only «Trials» results were includ in the meta-analysis (3) 6
7 emethods : list of vascular occlusive adverse events Acute myocardial infarction Angina pectoris Angina unstable Aortic stenosis Arterial occlusive disease Arterial stenosis limb Arteriosclerosis Arteriosclerosis coronary artery Atrial thrombosis Basilar artery stenosis Cardiac arrest Cardiac discomfort Cardiac infarction Cardiac ischaemia Cardiogenic shock Cardio-respiratory arrest Central nervous system lesion Cerebral infarction Cerebrovascular accident Cerebrovascular disorder Chest pain Coronary artery disease Coronary artery restenosis Coronary artery stenosis Deep vein thrombosis Dysarthria Electrocardiogram ST-segment depression Femoral arterial stenosis Hypoxic-ischemic encephalopathy Iliac artery stenosis Intermittent claudication Ischaemic heart disease Ischaemic stroke Mesenteric artery embolism Myocardial infarction Myocardial ischaemia Peripheral arterial occlusive disease Peripheral artery disease Peripheral artery thrombosis Peripheral vascular disorder Phlebitis Pulmonary embolism Retinal vein thrombosis Thrombophlebitis Thrombosis in device Transient ischaemic attack Varicose vein Vascular graft occlusion Vena cava thrombosis 7
8 efigure 1: Flow diagram of study selection according to PRISMA (preferr reporting items for systematic reviews and meta-analysis) statement. 8
9 etable 1: Characteristics of includ clinical trials and quality assessment Study ID BELA NCT NCT Study design Experimenta l Dosage Admin frequency bosutinib 500mg dasatinib 100mg Control Dosage Admin frequency 400 or 800mg No. of pt s Populati on CP CML newly diagnose d CP CML untreat Age (mean ± SD) ± % male Primary endpoint 56 CCyR at MMR rate at 1 Secondary endpoint(s) MMR, MCyR, CHR at 1 Safety Duration of response Pharmacokine tics Time to transformatio n to AP/BP HR year OS year relapse free survival Toxicity Jada d scor e START R NCT NCT DASISION NCT dasatinib 70mg twice daily dasatinib 100mg dasatinib 100mg twice daily 800mg 15 0 CP CML previousl y treat with 3 CML previousl y treat with 51 9 CP CML newly diagnose d 51 ± MCyR at 1 weeks 48.6 ± MMR rate at ± CCyR rate by 1 MCyR at any time Duration of MCyR CHR, CCyR, MMR Duration of CHR AEs, SAEs, deaths QoL, PK Deaths, AEs, SAEs Mian time to treatment failure, to PFS Time to MMR CCyR Safety Time to CCyR and MMR OS PFS MMR 3 NordCML00 6 NCT dasatinib 100mg 46 CP CML newly diagnose d dasatinib: 54 : Proportion of Ph+ CD34+/CD 38 bone marrow cells at 6 Fraction of Ph+ cells at 1 and 3 Molecular and cytogenetic responses at 3, 6, 1 and 18 3 ENESTnd NCT ENESTcmr NCT nilotinib 300mg twice daily nilotinib twice daily nilotinib twice daily 400 or 600mg CP CML newly diagnose d CP CML previousl y treat with nilotinib 300mg: 47 nilotinib : 47 Imatinib : 46 nilotinib: 46 : 5 nilotini b: 68 imatini b: Rate of MMR at 1 Rate of confirm best cumulative CMR within the 1st year Rate of durable MMR by 4 Progression to AP/BP CCyR Rate ruction in BCR ABL transcript levels Kinetics of CMR PFS, EFS and OS 3 9
10 RE NICE NCT nilotinib twice daily twice daily 43 CML early CP previousl y treat nilotinib: 45 : Cumulative rate of MMR at 1 Time and duration of MMR and CMR Cumulative rate of CMR, MMR and MR4.0 PFS Safety 1 EPIC NCT ponatinib 45mg 30 7 CP CML newly diagnose d 51.5 ± MMR at 1 MR rate at 3,6,9 and 1 Time to MR CCyR rate Safety OS, PFS 10
11 efigure : Evaluation of publications bias A. Vascular occlusive events Funnel Plot of Standard Error by Log Peto odds ratio 0 1 Standard Error Log Peto odds ratio 11
12 B. Overall survival Funnel Plot of Standard Error by Log Peto odds ratio 0 1 Standard Error Log Peto odds ratio 1
13 C. Major molecular response Funnel Plot of Standard Error by Log Peto odds ratio 0,0 0, 0,4 Standard Error 0,6 0,8 1,0 -,0-1,5-1,0-0,5 0,0 0,5 1,0 1,5,0 Log Peto odds ratio 13
14 etable : Rates of outcomes of interest across the includ studies stratifi by treatment A. Vascular occlusive events Study No. of events/total No. (%) Fix effect model Random effect model New generation TKI ORPETO (95%CI) ORPETO (95%CI) NCT (BELA) 3/48 (1.1) 1/51 (0.40).77 ( ).77 ( ) Bosutinib 3/48 (1.1) 1/51 (0.40).77 ( ).77 ( ) NCT /13 (0.81) 0/13 (0.00) 7.39 ( ) 7.39 ( ) NCT (START R) /101 (1.98) 0/49 (0.00) 4.46 ( ) 4.46 ( ) NCT /19 (0.00) 1/13 (7.69) 0.09 ( ) 0.09 ( ) NCT (DASISION) 8/58 (3.10) 1/58 (0.39) 4.86 ( ) 4.86 ( ) NCT (NordCML006) 1/ (4.55) 0/4 (0.00) 8.09 ( ) 8.09 ( ) Dasatinib 1/53 (.30) /467 (0.43) 3.86 ( ) 3.86 ( ) NCT (ENESTnd) 61/556 (10.97) 6/80 (.14) 3.31 ( ) 3.31 ( ) NCT (ENESTcmr) 6/101 (5.94) 1/103 (0.97) 4.45 ( ) 4.45 ( ) Nilotinib 67/657 (10.0) 7/383 (1.83) 3.4 ( ) 3.4 ( ) NCT (EPIC) 1/154 (7.79) 3/15 (1.97) 3.47 ( ) 3.47 ( ) Ponatinib 1/154 (7.79) 3/15 (1.97) 3.47 ( ) 3.47 ( ) Overall 94/1,58 (5.94) 13/1,53 (1.04) 3.45 ( ) 3.45 ( ) B. Overall survival Study No. of events*/total No. (%) Fix effect model Random effect model New generation TKI ORPETO (95%CI) ORPETO (95%CI) NCT (BELA) 44/48 (98.39) 41/51 (96.0).38 ( ).38 ( ) bosutinib 44/48 (98.39) 41/51 (96.0).38 ( ).38 ( ) NCT /13 (99.19) 13/13 (100.00) 0.14 ( ) 0.14 ( ) NCT (DASISION) 50/58 (97.00) 55/58 (99.00) 0.36 ( ) 0.36 ( ) NCT (NordCML006) / (100.00) 3/4 (95.83) 6.80 ( ) 6.80 ( ) dasatinib 394/403 (97.77) 397/405 (98.03) 0.4 ( ) 0.46 ( ) NCT (ENESTnd) 559/563 (99.9) 79/83 (98.59).1 ( ).1 ( ) NCT (ENESTcmr) 103/104 (99.04) 103/103 (100.00) 0.14 ( ) 0.14 ( ) nilotinib 66/667 (99.5) 38/386 (98.96) 1.51 ( ) 1.01 ( ) NCT (EPIC) 154/155 (99.35) 150/15 (98.68).00 ( ).00 ( ) ponatinib 154/155 (99.35) 150/15 (98.68).00 ( ).00 ( ) Overall 1,454/1,473 (98.71) 1,170/1,194 (97.99) 1.3 (0.67.3) 1.14 ( ) * Number of events represents the number of patients alive after one or two years of treatment C. Major molecular response Study No. of events/total No. (%) Fix effect model Random effect model New generation TKI ORPETO (95%CI) ORPETO (95%CI) NCT (BELA) 103/50 (41.00) 68/5 (7.00) 1.86 (1.9.70) 1.86 (1.9.70) bosutinib 103/50 (41.00) 68/5 (7.00) 1.86 (1.9.70) 1.86 (1.9.70) NCT /13 (47.15) 40/13 (3.5) 1.84 ( ) 1.84 ( ) NCT (START R) 9/101 (8.71) 6/49 (1.5).50 ( ).50 ( ) NCT (DASISION) 119/59 (45.95) 73/60 (8.08).15 ( ).15 ( ) NCT (NordCML006) 18/ (81.00) 11/4 (46.00) 4.33 ( ) 4.33 ( ) dasatinib 4/505 (44.36) 130/456 (8.51).17 ( ).17 ( ) NCT (RE NICE) 8/ (36.36) 7/1 (33.33) 1.14 ( ) 1.14 ( ) NCT (ENESTnd) 44/563 (43.34) 63/83 (.6).49 ( ).49 ( ) NCT (ENESTcmr) 0/4 (83.33) 15/8 (53.57) 3.77 ( ) 3.77 ( ) nilotinib 7/609 (44.66) 85/33 (5.60).45 ( ).45 ( ) NCT (EPIC) 8/10 (80.00) 5/13 (5.07) 4.95 ( ) 4.95 ( ) ponatinib 8/10 (80.00) 5/13 (5.07) 4.95 ( ) 4.95 ( ) Overall 607/1,374 (44.18) 88/1,053 (7.35). ( ). ( ) 14
15 efigure 3: One-way sensitivity analysis of the risk of vascular occlusive events in the leukemic population and stratifi by treatment 15
16 efigure 4: One-way sensitivity analysis for the overall survival at 1 year and for the major molecular response rate. A. Overall survival Overall survival Study name Tre atme nt ComparisonStatistics with study remov Peto odds ratio (95% Lower Upper CI) with study remov Point limit limit p-value NCT BELA bosutinib 0,80 0,36 1,8 0,600 NCT dasatinib 1,8 0,66,46 0,463 NCT DASISION dasatinib 1,90 0,89 4,06 0,098 NCT NordCML006 dasatinib 1,15 0,60,1 0,684 NCT ENESTnd nilotinib 1,05 0,51,16 0,891 NCT ENESTcmr nilotinib 1,8 0,66,46 0,463 NCT EPIC ponatinib 1,15 0,59,6 0,684 1,0 0,63,9 0,576 0,01 0, Imatinib New generation TKI B. Major molecular response Major molecular response Study name Treatment ComparisonStatistics with study remov Peto odds ratio (95% Lower Upper CI) with study remov Point limit limit p-value NCT BELA bosutinib,3 1,9,81 0,000 NCT dasatinib,7 1,89,7 0,000 NCT START-R dasatinib,0 1,85,6 0,000 NCT DASISION dasatinib,4 1,84,7 0,000 NCT NordCML006 dasatinib,19 1,84,60 0,000 NCT RE-NICE nilotinib,4 1,89,67 0,000 NCT ENESTnd nilotinib,09 1,70,58 0,000 NCT ENESTcmr nilotinib,19 1,84,60 0,000 NCT EPIC ponatinib,0 1,85,61 0,000, 1,87,63 0,000 0,01 0, Imatinib New generation TKI 16
Meta-analysis: Methodology
Meta-analysis: Methodology Example: Assessment of cardiovascular safety profile of new generation BCR-ABL TKIs in patients with CML Haguet Hélène 04/03/2016 Meta-analysis = statistical combination of results
CML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
Imatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
ELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
The BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
HOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)
We are updating the design of this site. Learn more. Try the new test version at https://clinicaltrials.gov/beta/ Show less Find Studies About Studies Submit Studies Resources About Site Trial record 1
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
IRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
Chronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
Guidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
SESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
Contemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
Accepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.
Accepted Manuscript Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors Pradnya Chopade, Luke P. Akard PII: S2152-2650(18)30343-4 DOI: 10.1016/j.clml.2018.06.029
Summary 1. Comparative effectiveness of ponatinib
Cost-effectiveness of ponatinib (Iclusig ) as indicated for adult patients with: (i) CP-, AP-, or BP- chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to
1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with
1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with both Nilotinib and Dasatinib. Nilotinib for the cardio
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
Oxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
CML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
How I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
The concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
Study Design and Endpoints
Complete Molecular Response (CMR) Rate With Nilotinib in Patients With CML-CP Without CMR After 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial Timothy P. Hughes, Jeffrey H.
New drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
What is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas
What is New in CML 2018 Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas Final Results CML-IV Molecular Response with Imatinib 1538 pts newly
BMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
CML Update 2016 Arthur 2016
CML Update 2016 Chronic Myeloid Leukemia Splenomegaly CML (3 phase disease) Increased white cells Malignant proliferation of myeloid white cells Initially mature cells a) chronic phase of disease Evolution
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
CML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
CML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
Chronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
What is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
Welcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
Executive summary Overview
Executive summary Overview In this appraisal, we have demonstrated that dasatinib is clinically more effective, as well as more cost effective, than imatinib, the current standard of care. In the pivotal
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
New drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
Does Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
Post ASH Actualités LMC
Post ASH 2014 - Actualités LMC Actualités de première ligne LMC PC ENESTnd (6 ans) Dasision (5 ans) EPIC Spirit France (5 ans) Spirit 2 UK (5 ans) ENESTnd: Mise à jour à 6 ans Design = 846 ults with wly
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:
Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned
RESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol 316A4-223 (B18717) 11 October 216 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved
Contemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
at least one dose interruption. perc noted the manufacturer of ponatinib issued a dose reduction recommendation in the PACE study; however, there are currently no data on the optimal starting dose for
NCCP Chemotherapy Protocol. Bosutinib Monotherapy
Bosutinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
Ponatinib in chronic myeloid leukaemia (CML) 2
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
Juan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
DAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
Management of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
Low doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
NEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California Progression
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Chronic Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
CML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
CML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
Dabigatran etexilate, the prodrug of dabigatran, an oral
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials Jonathan
pan-canadian Oncology Drug Review Final Clinical Guidance Report Ponatinib (Iclusig) for Chronic Myeloid Leukemia / Acute Lymphoblastic Leukemia
pan-canadian Oncology Drug Review Final Clinical Guidance Report Ponatinib (Iclusig) for Chronic Myeloid Leukemia / Acute Lymphoblastic Leukemia October 1, 2015 DISCLAIMER Not a Substitute for Professional
A COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA.
A COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA Melea Ward A dissertation submitted to the faculty of the University of
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
Horizon Scanning in Oncology
Horizon Scanning in Oncology Nilotinib (Tasigna ) for the 1 st -line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase DSD: Horizon Scanning in Oncology Nr. 15
Practical Guidance for the Management of CML in 2016
Practical Guidance for the Management of CML in 2016 Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive
CML Clinical Case Scenario
CML Clinical Case Scenario Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive Cancer Center at
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Received: 13 December 2017 Accepted: 17 December 2017 DOI: 10.1002/ajh.25011 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
New Anti Leukemic treatments deserve a Cardioncology approach. Guido Gini AOU «Ospedali Riuniti» Università Politecnica delle Marche Ancona
New Anti Leukemic treatments deserve a Cardioncology approach Guido Gini AOU «Ospedali Riuniti» Università Politecnica delle Marche Ancona CML Is Linked to a Single Cytogenetic Abnormality: The Philadelphia
517 Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML
517 Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML https://ash.confex.com/ash/2014/webprogram/paper66809.html Objective. SPIRIT 2 is the largest
CML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008
![CML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008](/thumbs/75/71485931.jpg "CML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008")
Novità dall EHA >> [ Leucemia mieloide cronica ] CML EHA: what s new? Relatore: G. MARTINELLI 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia mieloide cronica - Copyright FSE 1 CML EHA:
History of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
CML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
Acute Coronary Syndrome
ACUTE CORONOARY SYNDROME, ANGINA & ACUTE MYOCARDIAL INFARCTION Administrative Consultant Service 3/17 Acute Coronary Syndrome Acute Coronary Syndrome has evolved as a useful operational term to refer to
1794 Updating Long-Term Outcome of Intermittent Imatinib. (INTERIM) Treatment in Elderly Patients with Ph+-CML
738 What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) after Imatinib Loses Patent Exclusivity? https://ash.confex.com/ash/2014/webprogram/paper71699.html
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Dati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib Protocol Code Tumour Group Contact Physician ULKCMLP Leukemia Dr. Donna Forrest ELIGIBILITY:
Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
Molecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
Research Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience
Disease Markers Volume 216, Article ID 7531472, 5 pages http://dx.doi.org/1.1155/216/7531472 Research Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single
What is New in Leukemia & MPN in 2011?
Leukemia Update What Did We Learn from ASCO 211? Jorge Cortes, MD Department of Leukemia MD Anderson Cancer Center Houston, Texas What is New in Leukemia & MPN in 211? Cool things happening in MPN The
THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease
THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping?
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping? David Pham, PharmD PGY2 Hematology/Oncology Pharmacy Resident South Texas VA Health Care System
Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
Evaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada
Evaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada Jeffrey H. Lipton, Sergio Iannazzo, Silvia Chiroli, Lisa McGarry 06 CADTH
MRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
reconsideration of the perc Initial Recommendation, perc noted that a RCT would likely not be feasible beyond the second-line setting for patients in whom other TKI therapy is not appropriate because of
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis
Impact of Age on Efficacy and Toxicity of Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis Abstract 479 Giles FJ, Rea D, Baccarani M, Cross NCP, Steegmann